Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06097403 |
| Other study ID # |
cardiovascular complications |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
October 2023 |
| Est. completion date |
October 2024 |
Study information
| Verified date |
October 2023 |
| Source |
Assiut University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Prevalance of cardiovascular complications in children with COVID 19 in Assuit university
children hospital
Description:
In December 2019, coronavirus disease 2019 (COVID-19) was first described in Wuhan, China, in
patients complaining of flulike symptoms.1 The virus was isolated and identified as a new
strain of coronavirus, now named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2
) . Cardiovascular complications of COVID-19 have received less medical attention;
nevertheless, the first cases of myocarditis in COVID-19 patients have been reported,3, 4, 5,
6 and myocarditis has been recognized as the cause of death in some covid 19 patients.7
Pathology usually is focal within the myocardium, but there is a risk of arrhythmia as well
as progression to fulminant heart failure and cardiogenic shock.
Clinical presentation of SARS-CoV-2 myocarditis varies among cases. Some patients may present
with relatively mild symptoms, such as fatigue and dyspnea,4 , 5 whereas others report chest
pain or chest tightness on exertion.3 , 6 Many patients do deteriorate, showing symptoms of
tachycardia and acute-onset heart failure with cardiogenic shock.3, 4, 5 In these severe
cases, patients may also present with signs of right-sided heart failure, including raised
jugular venous pressure, peripheral edema, and right upper quadrant pain.10 The most emergent
presentation is fulminant myocarditis, defined as ventricular dysfunction and heart failure
within 2-3 weeks of contracting the virus.8 The early signs of fulminant myocarditis usually
resemble those of sepsis: the patient often presents febrile with low pulse pressure, cold or
mottled extremities, and sinus tachycardia.10 Myocarditis is an inflammatory disease of the
heart characterized by inflammatory infiltrates and myocardial injury without an ischemic
cause.8 The most commonly identifiable cause of myocarditis in the United States and other
developed countries is viral.9 , Arrhythmia is recognized as one of the possible clinical
manifestations of COVID-19 patients. One observational study of the clinical characteristics
of COVID-19 patients in Hubei, China, reported a 7.3% incidence of heart palpitations among
its 137 patients 13 Moreover, Wang et al reported that arrhythmia was a cause of intensive
care unit transfer in 44.4% of COVID- Coagulation and inflammatory parameters are mildly
altered in COVID-19 infection, whereas MIS-C is characterized by laboratory evidence of a
proinflammatory and procoagulant state
